Short-term, daily intake of yogurt containing Bifidobacterium animalis ssp. lactis Bf-6 (LMG 24384) does not affect colonic transit time in women

British Journal of Nutrition

Volumn 111, Issue 2, 2014, Pages 279-286

  Merenstein, Daniel J ^a   D'Amico, Frank ^b   Palese, Caren ^a   Hahn, Alexander ^a   Sparenborg, Jessy ^a   Tan, Tina ^a   Scott, Hillary ^a   Polzin, Kayla ^c   Kolberg, Lore ^c   Roberts, Robert ^d  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b St Margaret Memorial Hospital   (United States)

^c CARGILL INC   (United States)

^d PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

Cross over trials; Gastrointestinal function; Gastrointestinal transit; Probiotics

Indexed keywords

PLACEBO; PROBIOTIC AGENT; YOGHURT;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ABNORMAL FECES; ADULT; AGED; ARTICLE; BIFIDOBACTERIUM ANIMALIS; BLOATING; COLONIC TRANSIT TIME; CONSTIPATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; FLATULENCE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TRANSIT; HEADACHE; HUMAN; HUMAN EXPERIMENT; INTESTINAL DYSMOTILITY; LOSS OF APPETITE; MEDICAL HISTORY; MENSTRUAL IRREGULARITY; NAUSEA; NONHUMAN; NORMAL HUMAN; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; SELF REPORT; SHORT COURSE THERAPY; SUPPLEMENTATION; TREATMENT OUTCOME; VOMITING; BACTERIAL STRAIN; BOOTSTRAPPING; DIET SUPPLEMENTATION; FECES; INTESTINE FUNCTION; OUTCOME ASSESSMENT; ADOLESCENT; BIFIDOBACTERIUM; COLON; CONTROLLED CLINICAL TRIAL; MICROBIOLOGY; PHYSIOLOGY; YOUNG ADULT;

BIFIDOBACTERIUM ANIMALIS;

ADOLESCENT; ADULT; BIFIDOBACTERIUM; COLON; CROSS-OVER STUDIES; FEMALE; GASTROINTESTINAL TRANSIT; HUMANS; PROBIOTICS; YOGURT; YOUNG ADULT;

EID: 84896627954     PISSN: 00071145     EISSN: 14752662     Source Type: Journal    
DOI: 10.1017/S0007114513002237     Document Type: Article

References (29)

1. Pollan M (2013) Some of My Best Friends Are Germs. In New York Times Magazine.
2. Quigley EM (2008) Probiotics in functional gastrointestinal disorders: what are the facts? Curr Opin Pharmacol 8, 704-708.
3. Heizer WD, Southern S & McGovern S (2009) The role of diet in symptoms of irritable bowel syndrome in adults: a narrative review. J Am Diet Assoc 109, 1204-1214.
4. Kullen MJ & Bettler J (2005) The delivery of probiotics and prebiotics to infants. Curr Pharm Des 11, 55-74.
5. Bouhnik Y, Pochart P, Marteau P, et al. (1992) Fecal recovery in humans of viable Bifidobacterium sp ingested in fermented milk. Gastroenterology 102, 875-878.
6. Mohan R, Koebnick C, Schildt J, et al. (2006) Effects of Bifidobacterium lactis Bb12 supplementation on intestinal microbiota of preterm infants: a double-blind placebo controlled randomized study. J Clin Microbiol 44, 4025-4031.
7. Mohan R, Koebnick C, Schildt J, et al. (2008) Effects of Bifidobacterium lactis Bb12 supplementation on body weight, fecal pH, acetate, lactate, calprotectin, and IgA in preterm infants. Pediatr Res 64, 418-422.
8. Fukushima Y, Li S, Hara H, et al. (1997) Effect of follow up formula containing bifidobacteria (NAN BF) on fecal flora metabolites in healthy children. Biosci Microflora 16, 65-72.
9. Picard C, Fioramonti J, Francois A, et al. (2005) Review Article: bifidobacteria as probiotic agents-physiological effects and clinical benefits. Aliment Pharmacol Ther 22, 495-512.
10. Briczinski EP, Loquasto JR, Barrangou R, et al. (2009) Strain-specific genotyping of Bifidobacterium animalis subsp. lactis by using single-nucleotide polymorphisms, insertions, and deletions. Appl Environ Microbiol 75, 7501-7508.
11. Barrangou R, Briczinski EP, Traeger LL, et al. (2009) Comparison of the complete genome sequences of Bifidobacterium animalis subsp. lactis DSM 10140 and Bl-04. J Bacteriol 191, 4144-4151.
12. Cleophas TJ (1994) Interaction in crossover studies: a modified analysis with more sensitivity. J Clin Pharmacol 34, 236-241.
13. Mills EJ, Chan AW, Wu P, et al. (2009) Design, analysis, and presentation of crossover trials. Trials 10, 27.
14. Armitage P (1991) Should we cross off the crossover? Br J Clin Pharmacol 32, 1-2.
15. Cleophas TJ (1995) A simple analysis of crossover studies with one-group interaction. Int J Clin Pharmacol Ther 33, 322-327.
16. Meance S, Cayuela C, Raimondi A, et al. (2003) Recent advances in the use of functional foods: effects of the commercial fermented milk with Bifidobacterium animalis strain DN-173 010 and yoghurt strains on gut transit time in the elderly. Microb Ecol Health Dis 15, 15-22.
17. Fleiss JL (1989) A critique of recent research on the two-treatment crossover design. Control Clin Trials 10, 237-243.
18. Grizzle JE (1965) The two-period change-over design an its use in clinical trials. Biometrics 21, 467-480.
19. Senn S (2002) Crossover Trials in Clinical Research. West Sussex: Jon Wiley and Sons.
20. Metcalf AM, Phillips SF, Zinsmeister AR, et al. (1987) Simplified assessment of segmental colonic transit. Gastroenterology 92, 40-47
21. Drossman DA, Corazziari E, Talley NJ, et al. (editors) (2000) Rome II: The Functional Gastrointestinal Disorders. Diagnosis, Pathophysiology and Treatment: A Multinational Consensus, 2nd ed. McLean, VA: Degnon Associates.
22. Svedlund J, Sjodin I & Dotevall G (1988) GSRS-a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci 33, 129-134.
23. Lewis SJ & Heaton KW (1997) Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol 32, 920-924.
24. Ventura M, Reniero R & Zink R (2001) Specific identification and targeted characterization of Bifidobacterium lactis from different environmental isolates by a combined multiplex-PCR approach. Appl Environ Microbiol 67, 2760-2765.
25. Sempler J (2010) Smart Pill Data, personal communication with CP.
26. Rosner B (2009) Fundamentals of Biostatistics. Boston: Brooks/Cole.
27. Milliken G & Johnson D (1984) Analysis of Messy Data. New York, NY: Von Nostrand Reinhold Company.
28. Shen D (2006) Estimate Carryover Effect in Clinical Trial Crossover Designs. Wilmington, DE: AstraZeneca Pharmaceuticals. http://www.lexjansen.com/ pharmasug/2006/posters/po16.pdf.
29. Waller PA, Gopal PK, Leyer GJ, et al. (2011) Dose-response effect of Bifidobacterium lactis HN019 on whole gut transit time and functional gastrointestinal symptoms in adults. Scand J Gastroenterol 46, 1057-1064.